Adjunctive &agr;-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study The effect of alpha-lipoic acid (ALA) supplementation on cardiovascular risk factors in men with chronic spinal cord injury: a clinical trial Role of alpha-lipoic acid in the management of anemia in patients with chronic renal failure undergoing hemodialysis Effects of alpha-lipoic Acid on body weight in obese subjects. Study of comparative effects of antioxidants on insulin sensitivity in type 2 diabetes mellitus. Effects of Alpha Lipoic Acid on Multiple Cytokines and Biomarkers and Recurrence of Atrial Fibrillation Within 1 Year of Catheter Ablation. Effects of α-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. Effect of alpha-lipoic acid and vitamin E supplementation on oxidative stress, inflammation, and malnutrition in hemodialysis patients. Alpha-Linolenic Acid: Is It Essential to Cardiovascular Health? Impact of therapy with alpha-lipoic acid (ALA) on the oxidative stress in the controlled NIDDM: a possible preventive way against the organ dysfunction? Alpha-lipoic acid reduces body weight and regulates triglycerides in obese patients with diabetes mellitus. Effects of alpha lipoic acid supplementation on serum levels of IL-8 and TNF-α in patient with ESRD undergoing hemodialysis Randomized, triple-blind, placebo-controlled clinical trial examining the effects of alpha-lipoic acid supplement on the spermatogram and seminal oxidative stress in infertile men. A Preliminary Investigation of &agr;-Lipoic Acid Treatment of Antipsychotic Drug-Induced Weight Gain in Patients With Schizophrenia Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance
& agr;-Lipoic acid ( ALA ) has been reported to be effective in reducing body weight in rodents and obese patients . Our previous open trial showed that ALA may play a role in reducing weight gain in patients with schizophrenia on atypical antipsychotics . The present study evaluated the efficacy of ALA in reducing weight and BMI in patients with schizophrenia who had experienced significant weight gain since taking atypical antipsychotics . In a 12-week , double-blind r and omized placebo-controlled study , 22 overweight and clinical ly stable patients with schizophrenia were r and omly assigned to receive ALA or placebo . ALA was administered at 600–1800 mg , as tolerated . Weight , BMI , abdomen fat area measured by computed tomography , and metabolic values were determined . Adverse effects were also assessed to examine safety . Overall , 15 patients completed 12 weeks of treatment . There was significant weight loss and decreased visceral fat levels in the ALA group compared with the placebo group . There were no instances of psychopathologic aggravation or severe ALA-associated adverse effects . ALA was effective in reducing weight and abdominal obesity in patients with schizophrenia who had experienced significant weight gain since beginning an atypical antipsychotic regimen . Moreover , ALA was well tolerated throughout this study . ALA might play an important role as an adjunctive treatment in decreasing obesity in patients who take atypical antipsychotics Study design : A r and omized , double-blind , placebo-controlled clinical trial . Objective : To assess the effect of alpha-lipoic acid ( ALA ) supplementation on IL-6 , hs-CRP , FBS , anthropometric indices , food intake and blood pressure in male patients with chronic spinal cord injury ( SCI ) . Setting : Imam Khomeini Hospital , Tehran University of Medical Sciences , Tehran , Iran . Methods : Fifty-eight men with chronic SCI participated in the study . Participants were divided in two groups : one group received 600 mg of supplemental ALA ( n=28 ) and the other group received placebo ( n=30 ) for 12 weeks . At the beginning and end of the study , biochemical parameters , anthropometric indices , blood pressure and dietary intakes were measured . Dietary intake was measured using N4 software , and statistical analyses were carried out using SPSS16 . Results : No significant reduction was found in IL-6 ( P=0.97 ) and hs-CRP levels ( P=0.23 ) . There was significant reduction in fasting blood sugar ( P=0.001 ) , body weight ( P=0.001 ) , BMI ( P=0.001 ) , waist circumference ( P=0.001 ) and blood pressure ( P=0.001 ) . Dietary intake was significantly reduced , including fat ( P=0.001 ) , carbohydrate ( P=0.001 ) , protein ( P=0.002 ) and energy intakes ( P=0.001 ) . Conclusion : Lipoic acid supplementation had no significant effect on the measured inflammatory markers but it reduces fasting blood sugar , anthropometric parameters , food intake and blood pressure in men with chronic SCI Introduction Anemia associated with chronic kidney disease is a serious complication necessitating expenditure of huge medical efforts and re sources . This study investigates the role of alpha-lipoic acid ( ALA ) in end stage renal disease patients undergoing hemodialysis . By the virtue of its antioxidative effects , ALA is expected to act as an erythropoietin ( EPO ) adjuvant , and also has extended beneficial effects on endothelial dysfunction . Methods Forty-four patients undergoing hemodialysis and receiving EPO  were r and omized into two groups : the first group received ALA 600 mg once daily for 3 months ; while the other group represented the control group . Parameters measured at baseline and at end of study were hemoglobin , EPO doses , EPO resistance index ( ERI ) , iron store indices , malondialdehyde , oxidized low-density lipoprotein ( ox-LDL ) , interleukin-6 ( IL-6 ) , tumor necrosis factor-α ( TNF-α ) , and asymmetric dimethylarginine ( ADMA ) , as well as routine laboratory follow-up . Results EPO doses and ERI were significantly decreased in the treatment group , while they did not change in the control group . Hemoglobin , iron store indices , malondialdehyde , oxidized ox-LDL , IL-6 , TNF-α , and ADMA were similar in both treatment and control groups at baseline , and did not change by the end of study period . Likewise , routine laboratory measures were not affected by the treatment . Conclusion ALA could be used in hemodialysis patients to reduce requirements for EPO . However , larger and longer term studies are required to clarify the exact role of ALA in hemodialysis as well as in pre-hemodialysis patients PURPOSE alpha-lipoic acid is an essential cofactor for mitochondrial respiratory enzymes that improves mitochondrial function . We previously reported that alpha-lipoic acid markedly reduced body weight gain in rodents . The purpose of this study was to determine whether alpha-lipoic acid reduces body weight in obese human subjects . METHODS in this r and omized , double-blind , placebo-controlled , 20-week trial , 360 obese individuals ( body mass index [ BMI ] ≥ 30 kg/m(2 ) or BMI 27 - 30 kg/m(2 ) plus hypertension , diabetes mellitus , or hypercholesterolemia ) were r and omized  to alpha-lipoic acid 1200 or 1800 mg/d or placebo . The primary end point was body weight change from baseline to end point . RESULTS the 1800 mg alpha-lipoic acid group lost significantly more weight than the placebo group ( 2.1 % ; 95 % confidence interval , 1.4 - 2.8 ; P<.05 ) . Urticaria and itching sensation were the most common adverse events in the alpha-lipoic acid groups , but these were generally mild and transient . CONCLUSION alpha-lipoic acid 1800 mg/d led to a modest weight loss in obese subjects . Alpha-lipoic acid may be considered as adjunctive therapy for obesity OBJECTIVES This study intended to assess the effects of the antioxidants ; Alpha Lipoic Acid ( ALA ) , omega 3 fatty acids and vitamin E on the parameters of insulin sensitivity , oxidative stress , lipid metabolism and glycaemic control in patients of type 2 diabetes mellitus . METHODS This was a prospect i ve , r and omized , double blind , placebo controlled , single centred study . One hundred four patients with type 2 diabetes mellitus with insulin resistance were recruited for the study . They were given ALA , omega 3 fatty acids , vitamin E or placebo . Their weight , Body Mass Index ( BMI ) and Waist circumference were measured . The investigations which were fasting glucose and fasting total cholesterol . The insulin resistance was calculated on the basis of the BMI and the waist circumference . RESULTS In the intra group analysis at the baseline ( V1 ) vs at the end of the treatment period ( V5 ) , we observed a significant decrease in the BMI , waist circumference and the total cholesterol in the three treatment groups . In the intergroup analysis at V5 , ALA , omega 3 fatty acids and vitamin E showed a significant improvement in the total cholesterol as compared to the placebo and vitamin E showed the maximum improvement . CONCLUSION ALA , omega 3 fatty acids and vitamin E showed the improvement in insulin sensitivity . Since they differ in improving different parameters all of these three can be used as an add on therapy in patients with type 2 diabetes mellitus to improve their insulin sensitivity and lipid metabolism Catheter ablation ( CA ) is a procedure commonly used to restore sinus rhythm in patients with atrial fibrillation ( AF ) . However , AF recurrence after CA remains a relevant clinical issue . We tested the effects of an oral antioxidant treatment ( alpha lipoic acid [ ALA ] ) on AF recurrence post-CA . Patients with paroxysmal AF have been enrolled in a r and omized , prospect i ve , double-blind , controlled placebo trial . After CA , patients have been r and omly assigned to receive ALA oral supplementation ( ALA group ) or placebo ( control group ) and evaluated at baseline and after a 12-month follow-up : 73 patients completed the 12-month follow-up  ( ALA : 33 and control : 40 ) . No significant difference has been detected between the 2 groups at baseline . Strikingly , 1 year after CA , ALA therapy significantly reduced serum markers of inflammation . However , there was no significant difference in AF recurrence events at follow-up comparing ALA with placebo group . Multivariate analysis revealed that the only independent prognostic risk factor for AF recurrence after CA is age . In conclusion , ALA therapy reduces serum levels of common markers of inflammation in ablated patients . Nevertheless , ALA does not prevent AF recurrence after an ablative treatment OBJECTIVE To evaluate the potential body weight-lowering effects of dietary supplementation with eicosapentaenoic acid ( EPA ) and α-lipoic acid separately or combined in healthy overweight/obese women following a hypocaloric diet . METHODS This is a short-term double-blind placebo-controlled study with parallel design that lasted 10 weeks . Of the r and omized participants , 97 women received the allocated treatment  [ Control , EPA ( 1.3 g/d ) , α-lipoic acid ( 0.3 g/d ) , and EPA+α-lipoic acid ( 1.3 g/d+0.3 g/d ) ] , and 77 volunteers completed the study . All groups followed an energy-restricted diet of 30 % less than total energy expenditure . Body weight , anthropometric measurements , body composition , resting energy expenditure , blood pressure , serum glucose , and insulin and lipid profile , as well as leptin and ghrelin levels , were assessed at baseline and after nutritional intervention . RESULTS Body weight loss was significantly higher ( P<0.05 ) in those groups supplemented with α-lipoic acid . EPA supplementation significantly attenuated ( P<0.001 ) the decrease in leptin levels that occurs during weight loss . Body weight loss improved lipid and glucose metabolism parameters but without significant differences between groups . CONCLUSIONS The intervention suggests that α-lipoic acid supplementation alone or in combination with EPA may help to promote body weight loss in healthy overweight/obese women following energy-restricted diets INTRODUCTION Increased oxidative stress , inflammation , and malnutrition are present in hemodialysis patients and these factors exacerbate cardiovascular comorbidities . Vitamin E and alpha-lipoic acid ( ALA ) may have a protective role against cardiovascular disease risk factors via anti-oxidative and anti-inflammatory properties . The aim of this study was to evaluate the effect of ALA and vitamin E administration ( alone or combined ) on hemodialysis-induced stress oxidation , inflammation , and malnutrition . MATERIAL S AND METHODS In a r and omized placebo-controlled trial , we examined the effects of 2-month supplementation by vitamin E and ALA ( alone or combined ) on biomarkers of lipid peroxidation ( malondialdehyde ) , inflammation ( high-sensitivity C-Reactive protein and interleukin-6 ) , and malnutrition ( Subjective Global Assessment and body mass index ) in 85 hemodialysis patients receiving ALA ( 600 mg ) , vitamin E ( 400 IU ) , ALA and vitamin E , and placebo .  RESULTS After supplementation , no significant changes were observed in malondialdehyde level ; however , there was a decrease in the ALA and vitamin E group during the period of the study . Also , a nonsignificant decrease was seen in the high-sensitivity C-Reactive protein concentration of the interventional groups . Supplementation of vitamin E with and without ALA significantly reduced interleukin-6 concentration . A significant improvement was observed in malnutrition status of all groups . CONCLUSIONS Vitamin E and ALA supplementation , especially their combination , might improve inflammation and malnutrition status , which suggest it as a potential preventive strategy against CVD among end-stage renal disease patients There is a large body of scientific evidence that has been confirmed in r and omized controlled trials indicating a cardioprotective effect for omega-3 fatty acids from fish . For alpha-linolenic acid ( ALA ) , which is the omega-3 fatty acid from plants , the relation to cardiovascular health is less clear . We review ed the recent literature on dietary ALA intake , ALA tissue concentrations , and cardiovascular health in humans . Short-term trials ( 6–12 weeks ) in generally healthy participants mostly showed no or inconsistent effects of ALA intake ( 1.2–3.6 g/d ) on blood lipids , low-density lipoprotein oxidation , lipoprotein(a ) , and apolipoproteins A-I and B. Studies of ALA in relation to inflammatory markers and glucose metabolism yielded conflicting results . With regard to clinical cardiovascular outcomes , there is observational evidence for a protective effect against nonfatal myocardial infa rct ion . However , no protective associations were observed between  ALA status and risk of heart failure , atrial fibrillation , and sudden death . Findings from long-term trials of ALA supplementation are awaited to answer the question whether food-based or higher doses of ALA could be important for cardiovascular health in cardiac patients and the general population There is a growing evidence that excess generation of highly reactive free radicals , largely due to hyperglycemia , causes oxidative stress , which further exacerbates the development and progression of diabetes and its complications . The purpose of this study was to evaluate the impact of ALA on lipid profile , oxidative pattern and inflammation in patients with controlled non-insulin dependent diabetes mellitus ( NIDDM ) .  ALA , 400mg/day was investigated in NIDDM patients over a period of 4 weeks using a r and omized , placebo-(PLA)-controlled study with two parallel groups . The marker of oxidative stress was the concentration of reactive oxygen metabolites , evaluated using a commercially available test , called d-ROMs  test  , and the  biological antioxidant potential ( BAP ) ; besides , the lipid profile ( total cholesterol = TC , high-density lipoprotein-cholesterol = HDL-C ; low-density lipoprotein-cholesterol = LDL-C , and triglycerides = TG ) and the C-reactive protein ( CRP ) , marker of inflammation were measured at the beginning and at the end of the treatment . A total of 14 patients were r and omly assigned to the two groups . ALA was safe and well tolerated in the only oral daily administration . The d-ROMs test ( p=0.03 ) and HDL-C ( p=0.04 ) showed a significant difference between the two groups . BAP ( p=0.06 ) tended to be higher in the treated patients , while LDL-C ( p=0.07 ) presented a moderate decline . There were no significant differences in TC ( p=0.65 ) , TG ( p=0.78 ) and CRP ( p=0.96 ) between the ALA and PLA groups . ALA therapy appears to reduce significantly d-ROMs and to improve HDL-C value , especially in men with metabolic syndrome treated with oral hypoglycemic drugs . These findings will be useful in patient selection in future clinical trials with ALA in long term studies AIM To determine an influence of alpha-lipoic acid to reduction of body weight and regulation of total cholesterol concentration , triglycerides and glucose serum levels in obese patients with diabetes mellitus type 2 . METHODS A prospect i ve study includes two groups of obese patients with diabetes mellitus and signs of peripheral polyneuropathia : examined group ( 30 patients ; 15 females and 15 males ) , and control group ( 30 patients ; 12 females and 18 males ) . All were treated with metformin ( 850 - 1700 mg/day ) . Examined patients were additionally treated with alpha-lipoic acid 600 mg/day during 20 weeks . Body mass index and concentrations of total cholesterol , triglycerides and glucose in serum were compared before and after the treatment . RESULTS The group treated with 600 mg alpha-lipoic acid lost significantly more weight , and had lower triglyceride level than the control group . There were no significant differences in total cholesterol and glucose serum levels between the groups . CONCLUSION Alpha-lipoic acid of 600 mg/day treatment have influenced weight and triglycerides loss in obese patients with diabetes mellitus type 2 . It should be considered as an important additive therapy in obese patients with diabetes mellitus type 2 Background Chronic renal failure is a progressive and irreversible loss of kidney function , and the hemodialysis ( HD ) is one of the most common modalities in this regard . Oxidative stresses [ like interleukin-8 ( IL-8 ) and tumor necrosis factor-alpha ( TNF-α ) ] and inflammation are the main risk factors associated with cardiovascular diseases and other complications in many organs in hemodialysis patients ; meanwhile , antioxidants like alpha lipoic acid ( ALA ) may reduce the oxidative stress markers and the levels of inflammatory cytokines , so can improve of the patient ’s quality of life . Methods In this r and omized clinical trial study , 60 HD patients were r and omly categorized in two case and control groups . Case group received a daily capsule of 600 mg of ALA supplementation for 8 weeks , and the control group received placebo capsules daily . The serum level of IL-8 and TNF-α was measured in both groups before and after the intervention . Results There were no significant differences in age , gender , duration of dialysis , and causative factor for dialysis between both groups ( P > 0.05 ) . The mean of IL-8 and TNF-α after the intervention in case group was 26.20 ± 15.34 and 21.25 ± 9.61 , respectively ; the difference between both groups was not statistically significant ( P > 0.05 ) . Conclusion Based on the better feeling and other beneficial effects of ALA were found in our study ; we can conclude that it is a beneficial and recommended supplement , especially , for diabetic and dialysis patients OBJECTIVE To evaluate effects of supplementation with alpha-lipoic acid ( ALA ) on the spermatogram and seminal oxidative stress biomarkers . DESIGN R and omized , triple-blind , placebo-controlled clinical trial . SETTING Infertility clinic . PATIENT(S ) Infertile men . INTERVENTION(S ) ALA ( 600 mg ) or placebo for 12 weeks . MAIN OUTCOME MEASURE(S ) Semen analysis , anthropometric , dietary , and physical activity assessment s , total antioxidant capacity , and malondialdehyde . RESULT ( S ) At the end of study , the total sperm count , sperm concentration , and motility in the intervention group were significantly higher than in the control group . In the ALA group , the total sperm count , sperm concentration , and motility levels were also significantly increased at the end of study compared with baseline values . However , there were no significant differences in ejaculate volume , normal morphology percentage , and live sperm between groups . ALA supplementation also result ed in a significant improvement in seminal levels of total antioxidant capacity ( TAC ) and malondialdehyde compared with the placebo . CONCLUSION ( S ) According to the results , medical therapy of asthenoteratospermia with ALA supplement could improve quality of semen parameters . However , further investigation is suggested in this regard . CLINICAL TRIAL REGISTRATION NUMBER I RCT 2013111010181N3 Weight gain and other metabolic disturbances have now become discouraging , major side effects of atypical antipsychotic drugs ( AAPDs ) . The novel strategies required to counteract these serious consequences , however , should avoid modulating the activities of the neurotransmitter receptors involved because those receptors are the therapeutic targets of AAPDs . Adenosine monophosphate-activated protein kinase is an enzyme that plays a pivotal role in energy homeostasis . We hypothesized that & agr;-lipoic acid ( ALA ) , which is known to modulate adenosine monophosphate-activated protein kinase activity in the hypothalamus and peripheral tissues , would ameliorate AAPD-induced  weight gain . We describe the case series of a 12-week ALA trial in schizophrenia patients treated with AAPDs . Two of 7 enrolled subjects were dropped from the study because of noncompliance and dem and for new medication to treat depressive symptoms , respectively . The mean ( SD ) weight loss was 3.16 ( 3.20 ) kg ( P = 0.043 , last observation carried forward ; median , 3.03 kg ; range , 0 - 8.85 kg ) . On average , body mass index showed a significant reduction ( P = 0.028 ) over the 12 weeks . During the same period , a statistically significant reduction was also observed in total cholesterol levels ( P = 0.042 ) , and there was a weak trend toward the reduction in insulin resistance ( homeostasis model assessment of insulin resistance ) ( P = 0.080 ) . Three subjects reported increased energy subjectively . The total scores on the Brief Psychiatric Rating Scale and the Montgomery-Asberg Depression Rating Scale did not vary significantly during the study . These preliminary data suggest the possibility that ALA can ameliorate the adverse metabolic effects induced by AAPDs . To confirm the benefits of ALA , more extended study is warranted Despite well-controlled blood glucose levels , diabetic complications still inevitably take place via several mechanisms including excessive generation of free radicals in patients who suffer from diabetes mellitus ( DM ) . A r and omized double-blind placebo-controlled clinical trial to investigate the effectiveness of oral supplementation of DL-alpha-lipoic acid ( ALA ) on glycemic and oxidative status in DM patients was conducted . Thirty eight out patients with type 2 DM were recruited and r and omly assigned to either placebo or treatment in various doses of ALA ( 300 , 600 , 900 , and 1200 mg/day ) for 6 months . Following the treatment , all subjects were evaluated for glucose status and oxidative biomarkers . Results showed that fasting blood glucose , HbA1c trended to decrease in a dose-dependent manner . Increase of urinary PGF2α-Isoprostanes ( F2α-IsoP ) was noted in placebo but not ALA-treated groups , indicating possible suppressing action of ALA on lipid peroxidation in DM subjects . 8-Hydroxy-2'-deoxyguanosine ( 8-OHdG ) levels , however , were similar in both placebo and ALA groups as well as urinary microalbumin and serum creatinine . Safety evaluation was monitored and treatment was found to be well tolerated despite some minor side effects . Results from this study reflected the benefits of ALA in glucose status with slight efficiency on oxidative stress-related deterioration in DM patients OBJECTIVE To examine the effects of alpha-lipoic acid ( ALA ) treatment over a period of 2 months on fasting blood glucose ( FBG ) , insulin resistance ( IR ) , and glutathione peroxidase ( GH-Px ) activity in type 2 diabetes ( T2DM ) patients . METHODS This study took place in Motahari Clinic , Shiraz , Iran , which is affiliated to Shiraz University of Medical Sciences from May to October 2006 . Type 2 DM patients ( n=57 ) were divided into 2 groups to receive either ALA ( 300 mg daily ) or placebo by systematic r and omization , and were followed-up for 8 weeks . After an overnight fasting and 2 hours after breakfast , patients ' blood sample s were drawn and tested for FBG , 2 hours  PPG , serum insulin level , and GH-Px activity .  RESULTS The result of the study showed a significant decrease in FBG and PPG levels , IR-Homeostasis Model Assessment ( IR-HOMA index ) and GH-Px level in the ALA group . The comparison of differences between FBG and IR at the beginning and at the end of study in the ALA treated group and the placebo group were also significant . CONCLUSION This study supports the use of ALA as an antioxidant in the care of diabetic patients Obese subjects with impaired glucose tolerance ( IGT ) are more susceptible than healthy individuals to oxidative stress and cardiovascular disease . This r and omised controlled investigation was design ed to test the hypothesis that α-lipoic acid supplementation and exercise training may elicit favourable clinical changes in obese subjects with IGT . All data were collected from 24 obese ( BMI ≥ 30 kg/m2 ) IGT patients . Following participant r and omisation into two groups , fasting venous blood sample s were obtained at baseline , and before and following intervention . The first group consisted of 12 participants who completed a 12 week control phase followed by 12 weeks of chronic exercise at 65 % HRmax for 30 minutes a day , 5 days per week , while ingesting 1 gram per day of α-lipoic acid for 12 weeks . The second group consisted of 12 participants who completed the same 12 week control phase , but this was followed by 12 weeks of 1 gram per day of α-lipoic acid supplementation only ( no exercise ) . The main findings show a comparatively greater rate of low density lipoprotein ( LDL ) oxidation in the group consisting of α-lipoic acid only ( p < 0.05 vs. pre intervention ) , although total oxidant status was lower post intervention ( p < 0.05 vs. baseline ) in this group . However , exercise and α-lipoic acid in combination attenuates LDL oxidation . Furthermore , in the α-lipoic acid supplement plus exercise training  group , total antioxidant capacity was significantly increased ( p < 0.05 vs. baseline and pre intervention ) . Body fat percentage and waist and hip circumference decreased following exercise training ( p < 0.05 vs. post intervention ) . There were no selective treatment differences for a range of other clinical outcomes including glycaemic regulation ( p > 0.05 ) . These findings report that α-lipoic acid ingestion may increase the atherogenicity of LDL when ingested in isolation of exercise , suggesting that in IGT the use of this antioxidant treatment does not ameliorate metabolic disturbances , but instead may detrimentally contribute to the pathogenesis of atherosclerosis and development of CVD . However , when α-lipoic acid is combined with exercise , this atherogenic effect is abolished
The present study revealed that supplementation with ALA slightly but significantly decreased body weight and BMI .
Safe dosage for ALA is up to 1200 mg/day .
However , it seems that ALA can not be cost-effective .
BACKGROUND & AIMS Previous studies have supported positive roles of antioxidant supplements on  weight-loss .
One antioxidant supplement is Alpha-lipoic acid .
However , recommending ALA as an anti-obesity supplement remains controversial .
Accordingly , the purpose of the present study was to perform a meta- analysis on the effects of ALA supplement on anthropometric indices  among adult subjects .